RxDoctor Payments Data

James Robertson, MD

Obstetrics & Gynecology · Shreveport, LANPI 1669469961

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Intuitive Surgical at 39.5% of the total. Reporting peaked in 2024 at $4,543 and has fallen 99.5% since, to $23 in 2025. Among obstetrics & gynecology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,768in general payments, 2019–2025

Across 278 payments — averaging $38.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Coloplast$2K
  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$474
  • Caldera Medical, Inc$400
  • Currax Pharmaceuticals LLC$221
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$300%
  • Travel & lodging$3,90436%
  • Food & beverage$5,33350%
  • Education$1,50014%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,768 in reported general payments places this provider in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.

See all obstetrics & gynecology providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,083
Medicare patients
56
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide17$9,953
MyrbetriqMirabegron12$5,250
PremarinEstrogens, Conjugated15$4,815
Estradiol82$1,119
Medroxyprogesterone Acetate13$85
Citalopram HbrCitalopram Hydrobromide15$55
Fluconazole15$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,206$9,95317 claims
Astellas Pharma US IncMyrbetriq$54$5,25012 claims
PfizerPremarin$172$4,81515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.

Other obstetrics & gynecology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →